NewAmsterdam Pharma
Clinical trials sponsored by NewAmsterdam Pharma, explained in plain language.
NewAmsterdam Pharma
NAMS
NASDAQ
A biopharmaceutical company developing therapies for cardiovascular disease.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Healthy volunteers sought to test if experimental drug boosts antioxidant absorption. Results expected Sep 2026 (estimated) May already have reported ↗
- New combo aims to crush 'Bad' cholesterol particle that other drugs miss Results expected Nov 2026 (estimated)